Renal dysfunction in a renal transplant patient treated concurrently with cyclosporine and imatinib

Investigational New Drugs

Volumn 30, Issue 6, 2012, Pages 2400-2402

  Mulder, Karen E ^a,c   Egorin, Merrill J ^b   Sawyer, Michael B ^a,c  

^a UNIVERSITY OF ALBERTA   (Canada)

^b Departments of Medicine and Pharmacology and Cancer Center   (United States)

^c CROSS CANCER INSTITUTE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN; IMATINIB;

AGED; ARTICLE; BEDTIME DOSAGE; CADAVER KIDNEY; CASE REPORT; DISEASE COURSE; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; GASTROINTESTINAL STROMAL TUMOR; GRAFT RECIPIENT; HUMAN; KIDNEY DYSFUNCTION; KIDNEY TRANSPLANTATION; MALE; METASTASIS; MORNING DOSAGE; PRIORITY JOURNAL;

AGED; ANTINEOPLASTIC AGENTS; CYCLOSPORINE; GASTROINTESTINAL NEOPLASMS; GASTROINTESTINAL STROMAL TUMORS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY DISEASES; KIDNEY TRANSPLANTATION; MALE; PIPERAZINES; PROTEIN KINASE INHIBITORS; PYRIMIDINES;

EID: 84875532963     PISSN: 01676997     EISSN: 15730646     Source Type: Journal    
DOI: 10.1007/s10637-011-9769-3     Document Type: Article

References (15)

1. Blanke CD, Demetri GD, von Mehren M, Heinrich MC, Eisenberg B, Fletcher JA, Corless CL, Fletcher CD, Roberts PJ, Heinz D, Wehre E, Nikolova Z, Joensuu H (2008) Long-term results from a randomized phase II trial of standard-versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT. J Clin Oncol 26(4):620-625. doi:10.1200/JCO.2007.13.4403
2. Casper ES (2000) Gastrointestinal stromal tumors. Curr Treat Options Oncol 1:267-273. doi:10.1007/s11864-000-0039-4
3. DeMatteo RP, Lewis JJ, Leung D, Mudan SS, Woodruff JM, Brennan MF (2000) Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. Ann Surg 231:51-58. doi:10.1097/00000658-200001000-00008
4. Dagher R, Cohen M, Willliams G, Rothmann M, Gobburu J, Robbie G, Rahman A, Chen G, Staten A, Griebel D, Pazdur R (2002) Approval summary: imatinib mesylate in the treatment of metastatic and/or unresectable malignant gastrointestinal stromal tumors. Clinical Cancer Res 8:3034-3038
5. Fletcher CD, Berman JJ, Corless C, Gorstein F, Lasota J, Longley BJ, Miettinen M, O'Leary TJ, Remotti H, Rubin BP, Shmookler B, Sobin LH, Weiss SW (2002) Diagnosis of gastrointestinal stromal tumors: a consensus approach. Hum Pathol 33(5):459-465. doi:10.1053/hupa2002.123545
6. Parise RA, Ramanathan RK, Hayes MJ, Egorin MJ (2003) Liquid chromatographic-mass spectrometric assay for quantitation of imatinib and its main metabolite (CGP 74588) in plasma. Chromatogr B Analyt Technol Biomed Life Sci 791:39-44. doi:10.1016(51570-0232/03)00206-X
7. Kajita T, Higashi Y, Imamura M, Maida C, Fujii Y, Yamamoto I, Miyamoto E (2006) Effect of imatinib mesilate on the disposition kinetics of ciclosporin in rats. J Pharm Pharmacol 58(7):997-1000. doi:10.1211/jpp.58.7.0016
8. Yamada M, Miyamura K, Fujiwara T, Yokoyama H, Tomiya Y, Ishizawa K, Harigae H, Kameoka J, Saski T (2004) Imatinib mesylate in conjuction with allogeneic hematopoetic stem cell transplantation in patients with Philadelphia chromosome positive leukemias: report of 4 cases. Tohoku J Exp Med 204:79-84. doi:10.1620/tjem.204.79
9. Paul LC, de Fijter JH (2004) Cyclosporine induced renal dysfunction. Transplant Proc 3:224S-228S. doi:10.1016/jtransproceed.2004.01.005
10. Foringer JR, Verani RR, Tija VM, Finkel KW, Samuels JA, Guntupalli JS (2005) Acute renal failure secondary to imatinib mesylate treatment in prostate cancer. Ann Pharmacother 39 (12):2136-2138. doi:10.1345/aph.1G131
11. Francois H, Coppo P, Haymen JP, Fouqueray B, Mougenot B, Ronco P (2008) Partial Fanconi syndrome induced by imatinib therapy: a novel cause of urinary phosphate loss. Am J Kidney Dis 51(2):298-301. doi:10.1053/j.ajkd.2007.10.039
12. Chang H, Shih LY (2008) Imatinib-induced tumor lysis syndrome: report of a case and review of the literature. Chang Gung Med J 31:510-514
13. Gafter-Gvili A, Ram R, Gafter U, Shpilberg O, Raanani P (2010) Renal failure associated with tyrosine kinase inhibitors-case report and review of the literature. Leuk Res 34(1):123-127. doi:10.1016/j.leukres.2009.07.005
14. Judson I, Ma P, Peng B, Verweij J, Racine A, di Paola ED, van Glabbeke M, Dimitrijevic S, Scurr M, Dumez H, van Oosterom A (2005) Imatinib pharmacokinetics in patients with gastrointestinal stromal tumour: a retrospective population pharmacokinetic study over time-EORTC Soft Tissue and Bone Sarcoma Group. Cancer Chemother Pharmacol 55:379-386. doi:1007/s00280-004- 0876-0
15. Demetri GD, Wang Y, Wehrle E, Racine A, Nikolova Z, Blanke CD, Joensuu H, von Mehren M (2009) Imatinib plasma levels are correlated with clinical benefit in patients with unresectable/metastatic gastrointestinal stromal tumors. J Clin Oncol 27 (19):3156-3160. doi:10.1200/JCO, 2008.20.4818